Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company renowned for its customer-centric approach in the aesthetic market, will participate in the upcoming Leerink Partners Global Healthcare Conference in Miami, Florida. Members of Evolus's management team are scheduled for a fireside chat on Wednesday, March 11, 2026, at 11:20 AM ET. Investors and interested parties can access the discussion on the company's Investor Relations website, with a replay available for 90 days following the event.

Evolus is committed to redefining the aesthetic injectable market. The company has garnered attention for its flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), which is the first neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a distinctive line of injectable hyaluronic acid gels designed to enhance beauty. Evolus aims to position itself as a global leader in aesthetics by innovating and developing consumer-friendly products through a modern digital platform.

Founded on the principle of responding to the evolving needs of beauty consumers, Evolus distinguishes itself in a competitive industry. With a focus on cutting-edge solutions and an engaged customer base, the company is poised to capture a significant market share and reshape consumer experiences in aesthetic treatments.

For ongoing updates, Evolus encourages stakeholders to visit its official website and engage with the brand through various social media platforms including LinkedIn, X, Instagram, and Facebook. For further inquiries, investors can reach out to Nareg Sagherian, Vice President of Global Investor Relations and Corporate Communications, via phone or email.

For more details, including the official announcement, visit the [Business Wire](https://www.businesswire.com/news/home/20260225101738/en/).

Evolus, Inc. (NASDAQ: EOLS), recognized for its innovative approach in the aesthetics sector, is set to participate in the Leerink Partners Global Healthcare Conference, an event that presents a pivotal opportunity for both the company and potential investors. As the aesthetic injectable market continues to evolve, driven by rising consumer demand for non-invasive beauty treatments, Evolus stands at the forefront with its flagship product, Jeuveau®, the only neurotoxin exclusively dedicated to aesthetics.

Investors should pay close attention to the information shared during the fireside chat on March 11, 2026. Management's insights into the company's growth strategy, competitive positioning, and future plans could reveal valuable perspectives on Evolus’s trajectory, particularly as it navigates a complex and competitive market landscape. Given Evolus’s commitment to a customer-centric business model, it’s likely that we will hear about new initiatives aimed at enhancing customer engagement and brand loyalty.

From a financial perspective, the company's performance will be critical to evaluating its stock potential. Investors should closely monitor sales trends for Jeuveau® and Evolysse™, especially in light of emerging competitors. The financial metrics presented may provide insight into profit margins, operational efficiency, and market share dynamics—key indicators of sustainable growth.

Additionally, the ongoing developments in digital marketing strategies may also be highlighted, showing how Evolus plans to leverage technology to reach newer customer bases effectively.

As the conference approaches, those considering an investment in Evolus should remain vigilant regarding market reaction to the discussions, as positive sentiment could drive stock performance. In summary, participation in this conference is not just about information dissemination; it represents an opportunity for Evolus to reinforce its leadership position in a growing market, making it a compelling watch for investors.